(Q34424833)

2 August 2017

Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer (English)

1 reference

2 August 2017

1 reference

Natasa Todorović-Raković

1

1 reference

2 August 2017

Danica Jovanović

2

1 reference

2 August 2017

Zora Nesković-Konstantinović

3

1 reference

2 August 2017

Dragica Nikolić-Vukosavljević

4

1 reference

2 August 2017

language of work or name

1 reference

1 June 2005

1 reference

2 August 2017

Pathology International

1 reference

2 August 2017

55

1 reference

2 August 2017

6

1 reference

2 August 2017

318-323

1 reference

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

2 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2005.01831.X

ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2005.01831.X

Assessment of HER‐2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2005.01831.X

Emerging technologies for HER2 testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2005.01831.X

Evaluating HER2 amplification and overexpression in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2005.01831.X

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2005.01831.X

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2005.01831.X

Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2005.01831.X

Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2005.01831.X

Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2005.01831.X

Breast cancer in the 21st century: neu opportunities and neu challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2005.01831.X

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2005.01831.X

10.1111/J.1440-1827.2005.01831.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference